Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharm ; 10(9): 3275-84, 2013 Sep 03.
Article in English | MEDLINE | ID: mdl-23915336

ABSTRACT

The inability to deliver MAbs to intracellular targets still remains a limitation to their application in cancer therapy and diagnosis. Selective targeting of MAbs to oncoproteins in cancer cells while avoiding their accumulation in normal cells may reduce some of the well-documented adverse effects accompanying antibody therapy. One of the remarkable characteristics of malignant cells is the alteration in the biological properties of the cellular plasma membrane. Taking advantage of this alteration, we hope to selectively deliver self-associated MAb nanoparticles to cancer cells while reducing their accumulation in normal cells. We hypothesized that self-associated MAb nanoparticles can be preferentially taken up by non-small lung cancer cells in comparison to normal cells due to the absence or dysfunction of tight junctions (TJ) in confluent cancer cells and increased permeability of the cancer cell membrane. Self-associated bevacizumab nanoparticles were prepared and characterized for particle size and biochemical stability. Fluorescence microscopy, TEM, and flow cytometry revealed that these bevacizumab nanoparticles were internalized by A549 cells three times more than MRC-5 cells. Macropinocytosis and energy-dependent pathways were elucidated to be involved in their uptake by A549 cells. Further, uptake was by nonspecific interaction with cell membrane. Results obtained from this study suggest that self-associated MAb nanoparticles can be selectively delivered to cancer cells.


Subject(s)
Antibodies, Monoclonal/metabolism , Carcinoma, Non-Small-Cell Lung/metabolism , Nanoparticles/metabolism , Cell Line, Tumor , Endocytosis/physiology , Humans
2.
AAPS PharmSciTech ; 14(1): 200-10, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23255200

ABSTRACT

The ability to produce submicron particles of monoclonal antibodies of different sizes and shapes would enhance their application to pulmonary delivery. Although non-ionic surfactants are widely used as stabilizers in protein formulations, we hypothesized that non-ionic surfactants will affect the shape and size of submicron IgG particles manufactured through precipitation. Submicron particles of IgG1 were produced by a precipitation process which explores the fact that proteins have minimum solubility but maximum precipitation at the isoelectric point. Non-ionic surfactants were used for size and shape control, and as stabilizing agents. Aerosol performance of the antibody nanoparticles was assessed using Andersen Cascade Impactor. Spinhaler® and Handihaler® were used as model DPI devices. SEM micrographs revealed that the shape of the submicron particles was altered by varying the type of surfactant added to the precipitating medium. Particle size as measured by dynamic light scattering was also varied based on the type and concentration of the surfactant. The surfactants were able to stabilize the IgG during the precipitation process. Polyhedral, sponge-like, and spherical nanoparticles demonstrated improved aerosolization properties compared to irregularly shaped (>20 µm) unprocessed particles. Stable antibody submicron particles of different shapes and sizes were prepared. Careful control of the shape of such particles is critical to ensuring optimized lung delivery by dry powder inhalation.


Subject(s)
Aerosols , Immunoglobulin G/administration & dosage , Lung/metabolism , Surface-Active Agents/chemistry , Chromatography, High Pressure Liquid , Circular Dichroism , Enzyme-Linked Immunosorbent Assay , Immunoglobulin G/chemistry , Microscopy, Electron, Scanning , Particle Size , Spectrophotometry, Ultraviolet
3.
Dig Dis Sci ; 54(3): 675-82, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18594967

ABSTRACT

Glutathione depletion is a consistent feature of the progression of mild to severe acute pancreatitis. In this study, we examined the temporal relationship between cysteine, homocysteine, and cysteinyl-glycine levels; total reduced erythrocyte glutathione; gamma-glutamyl transpeptidase activity; and disease severity. Initially, cysteine concentration was low, at levels similar to those of healthy controls. However, glutathione was reduced whilst cysteinyl glycine and gamma-glutamyl transpeptidase activity were increased in both mild and severe attacks. As the disease progressed, glutathione and cysteinyl glycine were further increased in mild attacks and cysteine levels correlated with homocysteine (r = 0.8, P < 0.001) and gamma-glutamyl transpeptidase activity (r = 0.75, P < 0.001). The progress of severe attacks was associated with glutathione depletion, reduced gamma-glutamyl transpeptidase activity, and increased cysteinyl glycine that correlated with glutathione depletion (r = 0.99, P = 0.01). These results show that glutathione depletion associated with severe acute pancreatitis occurs despite an adequate cysteine supply and could be attributed to heightened oxidative stress coupled to impaired downstream biosynthesis.


Subject(s)
Cysteine/blood , Dipeptides/blood , Glutathione/metabolism , Homocysteine/blood , Pancreatitis/blood , APACHE , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/metabolism , Case-Control Studies , Erythrocytes/metabolism , Female , Glutathione/blood , Humans , Male , Middle Aged , Young Adult , gamma-Glutamyltransferase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...